Irinophore C™, liposomal vincristine and Caelyx
® significantly inhibits tumor growth, decreases proliferation and increases tumor perfusion in subcutaneous GBM tumors. a) Representative H&E sections of tumors from each treatment group show the efficacy of the treatments in controlling tumor growth. Arrow heads indicate enlarged nuclei associated with Caelyx® treatment. Tumor weights were calculated on the basis of caliper measurements; arrows indicate the treatment days. The Irinophore C™ statistical significance is indicated by bottom stars, while Caelyx® and liposomal vincristine statistical significances are indicated by top stars (*p-value ≤ 0.05; **p-value ≤ 0.01; ***p-value ≤ 0.001) b) The area of viable tissue in tumor sections following treatment was expressed in number of pixels and correlates well with tumor volumes (■, left axis). The fraction of viable, actively proliferating cells (■, right axis) in the tumors was significantly decreased by Irinophore C™. Ki67 staining was also increased in Caelyx®-treated tumors. c) Hoechst 33342 perfusion in the tumors was increased significantly by Irinophore C™ and Caelyx® treatment (■, left axis). The number of endothelial cells per unit area of viable tissue was unchanged by the treatments (■, right axis); however, the fraction of endothelial cells that were perfused (CD31 and Hoechst 33342 positive; □, right axis) was increased by treatment with Caelyx®. Statistical significances are indicated (*p-value ≤ 0.05; **p-value ≤ 0.01; ***p-value ≤ 0.001).